About this Research Topic
Liver cancer shows a worrisome epidemiological trend and became a major health issue. Estimates anticipate an increasing incidence worldwide, predicting that it will affect over 1 million of individuals per year by 2025. Unlike most other cancers, the mortality associated with liver cancer is rising. With the ongoing trend, its cancer-related mortality will rank third by 2030. The management of liver cancer follows guidelines that essentially rely on clinical variables but this approach showed a mitigated success.
Liquid biopsy - the molecular analysis of tumor by-products released by a solid tumor into the bloodstream - has emerged as a fantastic source of biomarkers. Those include a variety of cellular components: circulating tumor DNA (ctDNA), circulating-free RNA (cfRNA), circulating tumor cells (CTCs) and extracellular vesicles (EVs).Numerous studies illustrated the various potential applications of this technology in the management of cancers, including liver cancer.
This Research Topic aims to provide an updated and thorough overview of liquid biopsy in liver cancer, either with novel data from original studies or with comprehensive reviews.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
Keywords: Hepatocellular Carcinoma, ctDNA, Bile Duct Cancer, Cholangiocarcinoma, cfRNA
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.